These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey. Peyrin-Biroulet L; Lönnfors S; Avedano L; Danese S United European Gastroenterol J; 2019 Dec; 7(10):1345-1352. PubMed ID: 31839960 [TBL] [Abstract][Full Text] [Related]
3. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations. Peyrin-Biroulet L; Lönnfors S; Roblin X; Danese S; Avedano L J Crohns Colitis; 2017 Jan; 11(1):128-133. PubMed ID: 27481878 [TBL] [Abstract][Full Text] [Related]
4. Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey. D'Amico F; Peyrin-Biroulet L; Danese S J Clin Med; 2024 May; 13(11):. PubMed ID: 38892780 [No Abstract] [Full Text] [Related]
5. Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians. Park SK; Moon W; Kim ES; Park SH; Park DI Korean J Gastroenterol; 2019 Dec; 74(6):333-340. PubMed ID: 31870139 [TBL] [Abstract][Full Text] [Related]
6. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382 [TBL] [Abstract][Full Text] [Related]
7. Biosimilars in ulcerative colitis: When and for who? Ilias A; Gonczi L; Kurti Z; Lakatos PL Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937 [TBL] [Abstract][Full Text] [Related]
8. Patient and Caregivers' Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel Disease. Yossef L; Wright M; Benedict J; Morris GA; McNicol M; Boyle B; Dotson JL; Michel HK; Maltz RM J Pediatr Gastroenterol Nutr; 2022 Jul; 75(1):59-63. PubMed ID: 35442227 [TBL] [Abstract][Full Text] [Related]
9. Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease. Macaluso FS; Leone S; Previtali E; Ventimiglia M; Armuzzi A; Orlando A; Dig Liver Dis; 2020 Nov; 52(11):1304-1309. PubMed ID: 32807691 [TBL] [Abstract][Full Text] [Related]
10. Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus. D'Amico F; Solitano V; Magro F; Olivera PA; Halfvarson J; Rubin D; Dignass A; Al Awadhi S; Kobayashi T; Queiroz NSF; Calvo M; Kotze PG; Ghosh S; Peyrin-Biroulet L; Danese S J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37834994 [TBL] [Abstract][Full Text] [Related]
11. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. Avila-Ribeiro P; Fiorino G; Danese S Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114 [TBL] [Abstract][Full Text] [Related]
12. Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease. Rusch C; Wood M; Kennedy AG; Tompkins BJ; Frasca JD J Clin Pharm Ther; 2022 Nov; 47(11):1851-1857. PubMed ID: 36134561 [TBL] [Abstract][Full Text] [Related]
13. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Haghnejad V; Le Berre C; Dominique Y; Zallot C; Guillemin F; Peyrin-Biroulet L Dig Liver Dis; 2020 Mar; 52(3):281-288. PubMed ID: 31648920 [TBL] [Abstract][Full Text] [Related]
15. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017. Scott FI; Lichtenstein GR Curr Treat Options Gastroenterol; 2018 Mar; 16(1):147-164. PubMed ID: 29492747 [TBL] [Abstract][Full Text] [Related]
16. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review. Martelli L; Peyrin-Biroulet L Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715 [TBL] [Abstract][Full Text] [Related]
17. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A; Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085 [TBL] [Abstract][Full Text] [Related]
18. Biosimilars of adalimumab: the upcoming challenge in IBD. Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098 [No Abstract] [Full Text] [Related]
19. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Gulacsi L; Pentek M; Rencz F; Brodszky V; Baji P; Vegh Z; Gecse KB; Danese S; Peyrin-Biroulet L; Lakatos PL Curr Med Chem; 2019; 26(2):259-269. PubMed ID: 28393687 [TBL] [Abstract][Full Text] [Related]
20. Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group. Dipasquale V; Martinelli M; Aloi M; Accomando S; Alvisi P; Arrigo S; Banzato C; Bramuzzo M; Cananzi M; Corpino M; Di Mari C; Di Nardo G; Dilillo A; Dodaro N; Felici E; Gatti S; Graziano F; Illiceto MT; Norsa L; Opramolla A; Pastore M; Pavanello PM; Romeo E; Scarallo L; Strisciuglio C; Zuin G; Romano C Paediatr Drugs; 2022 Jan; 24(1):57-62. PubMed ID: 34914084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]